Underutilized Pharma Services And Execution Risks Will Threaten Demand Yet Efficiency Will Emerge

Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

07 Aug 25

Updated

03 Sep 26

Views

Not Invested

Shared on 03 Sep 26

Fair value Increased 45%

NEO: Expanded Coverage And Legal Win Will Support But Limit Future Upside

NeoGenomics gets wider Medicare coverage for a key cancer test and a court ruling removes a major patent roadblock, both of which could help demand and confidence. At the same time, the company updates its outlook, settles a government matter, and launches a new FDA-approved companion diagnostic—details that may shape how much upside investors can expect from here.

3 views

Shared on 08 Jul 26

Fair value Decreased 15%

NEO: Strong Testing Momentum Will Be Tempered By Rich Earnings Multiple

NeoGenomics’ cancer testing business shows fresh momentum, and a new ordering setup inside a major hospital records system could make it easier for doctors to use its tests more often. But analysts still cut their view of the stock, saying the market may be expecting too much from future profits despite the upbeat results and recent financing move.

3 views

Shared on 03 Apr 26

Fair value Increased 8.33%

NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026

Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).

6 views

Shared on 05 Feb 26

Fair value Increased 85%

NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data

Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.

3 views

Underutilized Pharma Services And Execution Risks Will Threaten Demand Yet Efficiency Will Emerge

NEO: Expanded Coverage And Legal Win Will Support But Limit Future Upside

NEO: Strong Testing Momentum Will Be Tempered By Rich Earnings Multiple

NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026

NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data

Fair Value vs Share Price

Recent News & Updates

Recent updates

Stay ahead on NeoGenomics

Company analysis

CEO & management